



Regulatory Sciences as applicable to Cannabis for Medicinal and Research Purposes

29-30 May, Malta Life Sciences Park, San Ġwann, MALTA

Addressed by:

Hon Dr Deo Debattista
Parliamentary Secretary for Consumer Rights, Public Cleansing & Support for the Capital City
Professor Anthony Serracino Inglott
Chairperson, Malta Medicines Authority

Speakers and contributors:

Dr Burt Kroes, Lucinda Wells, Pete Gough, Andrew Thornley, TOPRA
Luana Mifsud Buhagiar, Director for Advanced Scientific Initiatives, Malta Medicines Authority
Dr Mark Cilia, Director for Inspectorate and Enforcement, Malta Medicines Authority
Professor Everaldo Attard, Herbal expert, Malta Medicines Authority

Training outline

Practical overview on EU regulation of medicines and herbals, good practices, quality standards and guidance documents.

Target audience

Professionals with a patient-centered interest in cannabis for medicinal and research purposes, including representatives from industry, legal, recruitment and consultancy firms, project management, clinical and regulatory operations.

09:30	Introduction and welcome
10:00	Scope and objectives
10:15	The regulatory framework for medicines in the EU, including distinction between authorised medicinal products and other cannabis-based products
10:45	Medicinal product development process
11:30	Non-clinical development
12:15	The European clinical trials process
13:00	Lunch
14:00	EU Marketing Authorisation Application dossiers, including well-established use
14:45	How medicinal products are registered and approval maintained – EU marketing application procedures (national, DCP, MRP, CP)
15:30	Safety surveillance
16:00	Coffee Break
16:15	Lifecycle management – variations, extensions
16:45	Regulatory strategy – generics, information protection, early access, trade names, scientific advice
17:30	Overview and interactive quiz
18:30	Transport from MLSP to social event
19:30	Networking refreshments at The Sheer Bastion, Senglea
22:30	Transport from social event to MLSP

09:30	Cannabis for medicinal use – the local scenario
10:00	The scenario in the Netherlands
10:30	Quality, Pharmacopoeial standards and EMA guidance
11:00	CTD dossier for herbals
11:30	GACP
12:00	GMP with focus on cannabis dosage forms such as dried flowers and oils
12:30	Panel discussion and Q&A
13:00	Lunch
14:00	Duties and responsibilities in manufacturing – QP, QA, QC
14:30	Workshops
16:00	Coffee Break
16:15	Consolidation, including common pit-falls in the field
17:00	Feedback and evaluation
17:30	Close